TY - JOUR
T1 - Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL)
AU - Giglio, Auro Del
AU - O'brien, Susan
AU - Ford, Richard J.
AU - Manning, John
AU - Saya, Hideyuki
AU - Keating, Michael
AU - Johnston, Dennis
AU - Chamone, Dalton Fisher
AU - Deisseroth, Albert B.
N1 - Funding Information:
Attnowledgements The authors recognize support to Albert Deisseroth from the Kleberg Foundation, the Anderson Chair for Cancer Treatment and Research, the Sid Richardson Foundation, and the Ladies Leukemia League of Louisiana.
PY - 1993
Y1 - 1993
N2 - Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.
AB - Chronic Lymphocytic Leukemia (CLL) is usually an indolent disorder which in some patients assumes an aggressive clinical course. In order to assess at presentation the prognosis of a given patient, several staging systems and prognostic variables have been proposed including the expression of the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kd nuclear protein, the regulation of which is cell cycle-dependent. In CLL, PCNA levels correlate with cell proliferation, clinical stage and the lymphocyte doubling time (LDT). Furthermore, preliminary data suggests that PCNA expression may also predict response to Fludarabine-based chemotherapy. Since PCNA is a cofactor for Delta DNA polymerase, PCNA overexpression in CLL may also reflect the intrinsic DNA repair activity of the leukemic cells and thus their resistance to chemotherapy. Further studies aiming at modulation of PCNA expression in CLL cells may clarify this issue and may offer a future new therapeutic strategy with which to treat this disorder.
UR - http://www.scopus.com/inward/record.url?scp=0027267449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027267449&partnerID=8YFLogxK
U2 - 10.3109/10428199309148548
DO - 10.3109/10428199309148548
M3 - Article
C2 - 8106065
AN - SCOPUS:0027267449
SN - 1042-8194
VL - 10
SP - 265
EP - 271
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4-5
ER -
